• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

缺氧通过HIF-2α/COX-2促进786-O细胞的侵袭性和对索拉非尼的抗性。

Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.

作者信息

Zhao Chun-Xiong, Luo Chun-Li, Wu Xiao-Hou

机构信息

Department of Urology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.

出版信息

Med Oncol. 2015 Jan;32(1):419. doi: 10.1007/s12032-014-0419-4. Epub 2014 Dec 7.

DOI:10.1007/s12032-014-0419-4
PMID:25487445
Abstract

Accumulating evidences indicated that hypoxia-induced factors and COX-2 play a important role in tumorigenesis in various human cancer. Yet, the relationship between HIFs and COX-2 in human renal cancer remains unclear. The present study was to examine the role of HIFs and COX-2 in the invasiveness and the resistance to target agent in renal cancer cell line (786-O). In 786-O cells, hypoxia induced the increase in the protein expression of HIF1 and HIF2. We also demonstrate that hypoxia up-regulated the protein expression of COX-2 and Snail, but down-regulation of E-cadherin expression in 786-O cells promoted the invasiveness of 786-O cells and enhanced the resistance of 786-O cells to sorafenib. siRNA target to HIF1α, HIF2α and NS398, a selective inhibitor of COX-2, were used in this study. Only siRNA-HIF2α significantly suppressed the protein expression of HIF2 and COX-2, then decreased the invasive ability and resistance of 786-O cells to sorafenib under hypoxia. NS398 attenuated the increase in invasive cells number and the IC50 value of sorafenib induced by hypoxia. In conclusion, our results demonstrated that hypoxia promoted the invasiveness and resistance of 786-O cells to sorafenib via HIF2 and COX-2 and induced the activation of Snail/E-cadherin, suggesting that a signalling mechanism involving HIF2/COX2 modulates invasiveness and resistance to sorafenib in 786-O cells under hypoxia.

摘要

越来越多的证据表明,缺氧诱导因子和环氧化酶-2(COX-2)在多种人类癌症的肿瘤发生中起重要作用。然而,在人类肾癌中,缺氧诱导因子与COX-2之间的关系仍不清楚。本研究旨在探讨缺氧诱导因子和COX-2在肾癌细胞系(786-O)侵袭性及对靶向药物耐药性中的作用。在786-O细胞中,缺氧诱导缺氧诱导因子1(HIF1)和缺氧诱导因子2(HIF2)蛋白表达增加。我们还证明,缺氧上调了786-O细胞中COX-2和Snail的蛋白表达,但E-钙黏蛋白表达下调促进了786-O细胞的侵袭性,并增强了786-O细胞对索拉非尼的耐药性。本研究使用了针对HIF1α、HIF2α的小干扰RNA(siRNA)以及COX-2的选择性抑制剂NS398。只有siRNA-HIF2α显著抑制了HIF2和COX-2的蛋白表达,进而降低了缺氧条件下786-O细胞的侵袭能力及对索拉非尼的耐药性。NS398减弱了缺氧诱导的侵袭细胞数量增加及索拉非尼的半数抑制浓度(IC50)值。总之,我们的结果表明,缺氧通过HIF2和COX-2促进了786-O细胞的侵袭性及对索拉非尼的耐药性,并诱导了Snail/E-钙黏蛋白的激活,提示在缺氧条件下,一种涉及HIF2/COX2的信号机制调节了786-O细胞的侵袭性及对索拉非尼的耐药性。

相似文献

1
Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.缺氧通过HIF-2α/COX-2促进786-O细胞的侵袭性和对索拉非尼的抗性。
Med Oncol. 2015 Jan;32(1):419. doi: 10.1007/s12032-014-0419-4. Epub 2014 Dec 7.
2
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.索拉非尼诱导的HIF-2α上调通过激活肝癌细胞中的TGF-α/EGFR途径导致耐药。
Cell Signal. 2014 May;26(5):1030-9. doi: 10.1016/j.cellsig.2014.01.026. Epub 2014 Jan 29.
3
Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness.Cox-2 在人乳腺癌细胞中的表达作为上皮间质转化和侵袭性的关键决定因素。
Expert Opin Ther Targets. 2014 Feb;18(2):121-35. doi: 10.1517/14728222.2014.860447. Epub 2013 Dec 11.
4
COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.COX-2/PGE2 轴调节 HIF2α 活性以促进肝细胞癌缺氧反应并降低索拉非尼治疗的敏感性。
Clin Cancer Res. 2018 Jul 1;24(13):3204-3216. doi: 10.1158/1078-0432.CCR-17-2725. Epub 2018 Mar 7.
5
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.二甲双胍可使索拉非尼在原位小鼠模型中更有效地抑制肝细胞癌术后复发和转移。
J Hematol Oncol. 2016 Mar 8;9:20. doi: 10.1186/s13045-016-0253-6.
6
Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression.缺氧诱导因子1α和2α对结直肠癌患者的预后影响:与肿瘤血管生成和环氧合酶-2表达的相关性
Clin Cancer Res. 2004 Dec 15;10(24):8554-60. doi: 10.1158/1078-0432.CCR-0946-03.
7
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.缺氧介导的索拉非尼耐药可以通过 EF24 克服,EF24 通过 Von Hippel-Lindau 肿瘤抑制因子依赖性 HIF-1α 抑制在肝细胞癌中发挥作用。
Hepatology. 2013 May;57(5):1847-57. doi: 10.1002/hep.26224. Epub 2013 Mar 14.
8
Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells.缺氧诱导因子 1α介导表皮生长因子诱导的人卵巢癌细胞中 E-钙黏蛋白表达下调和细胞侵袭。
Cancer Lett. 2013 Feb 28;329(2):197-206. doi: 10.1016/j.canlet.2012.10.029. Epub 2012 Nov 8.
9
2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.2-甲氧基雌二醇通过同时失调缺氧诱导因子-1 和 -2 协同索拉非尼抑制肝细胞癌。
Cancer Lett. 2014 Dec 1;355(1):96-105. doi: 10.1016/j.canlet.2014.09.011. Epub 2014 Sep 11.
10
The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.缺氧诱导因子-1α 和 -2α 在雄激素非依赖性前列腺癌细胞中的作用。
Urol Oncol. 2013 Nov;31(8):1448-56. doi: 10.1016/j.urolonc.2012.03.022. Epub 2012 Apr 25.

引用本文的文献

1
Hypoxic stimulation of DCLK1 transcription and alternative-promoter switching fuels tumor malignancy in clear cell renal cell carcinoma.低氧刺激双皮质素样激酶1(DCLK1)转录及替代启动子切换促进透明细胞肾细胞癌的肿瘤恶性进展。
Cell Death Dis. 2025 Aug 7;16(1):594. doi: 10.1038/s41419-025-07916-2.
2
Emerging trends and knowledge networks in pan-cancer sorafenib resistance: a 20-year bibliometric investigation.泛癌索拉非尼耐药的新兴趋势与知识网络:一项为期20年的文献计量学调查
Front Pharmacol. 2025 Jul 23;16:1581820. doi: 10.3389/fphar.2025.1581820. eCollection 2025.
3
Evidence for Functional Regulation of the KLHL3/WNK Pathway by O-GlcNAcylation.

本文引用的文献

1
Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells.Wnt信号通路的下调减轻了缺氧诱导的人骨肉瘤细胞的化疗耐药性。
PLoS One. 2014 Oct 27;9(10):e111431. doi: 10.1371/journal.pone.0111431. eCollection 2014.
2
Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry.索拉非尼治疗肾细胞癌患者的预后因素:来自捷克登记处的结果。
Target Oncol. 2015 Sep;10(3):385-92. doi: 10.1007/s11523-014-0343-8. Epub 2014 Oct 12.
3
Cyclooxygenase-2 and the inflammogenesis of breast cancer.
O-连接的N-乙酰葡糖胺糖基化对KLHL3/WNK途径进行功能调控的证据
bioRxiv. 2025 Feb 27:2025.02.27.640596. doi: 10.1101/2025.02.27.640596.
4
Effects of hypoxia stress on the milk synthesis in bovine mammary epithelial cells.低氧应激对奶牛乳腺上皮细胞中乳合成的影响。
J Anim Sci Biotechnol. 2025 Mar 7;16(1):37. doi: 10.1186/s40104-025-01174-0.
5
Dense Collagen I as a Biomimetic Material to Track Matrix Remodelling in Renal Carcinomas.致密I型胶原蛋白作为一种仿生材料用于追踪肾癌中的基质重塑
ACS Omega. 2024 Sep 28;9(40):41419-41432. doi: 10.1021/acsomega.4c04442. eCollection 2024 Oct 8.
6
Integrating tumor and healthy epithelium in a micro-physiology multi-compartment approach to study renal cell carcinoma pathophysiology.采用微生理多室方法整合肿瘤与健康上皮组织以研究肾细胞癌病理生理学。
Sci Rep. 2024 Apr 23;14(1):9357. doi: 10.1038/s41598-024-60164-w.
7
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions.缺氧微环境与癌症:分子机制与治疗干预。
Signal Transduct Target Ther. 2023 Feb 17;8(1):70. doi: 10.1038/s41392-023-01332-8.
8
Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma.喜树碱通过抑制肝癌细胞 Nrf2-ARE 通路增强索拉非尼敏感性。
Oncol Rep. 2023 Mar;49(3). doi: 10.3892/or.2023.8492. Epub 2023 Feb 3.
9
Exploring Nitric Oxide (NO)-Releasing Celecoxib Derivatives as Modulators of Radioresponse in Pheochromocytoma Cells.探索一氧化氮(NO)释放塞来昔布衍生物作为嗜铬细胞瘤细胞放射反应调节剂。
Molecules. 2022 Oct 5;27(19):6587. doi: 10.3390/molecules27196587.
10
In Vitro Characterization of Renal Drug Transporter Activity in Kidney Cancer.在肾癌中对肾脏药物转运体活性的体外特征分析。
Int J Mol Sci. 2022 Sep 5;23(17):10177. doi: 10.3390/ijms231710177.
环氧化酶-2与乳腺癌的炎症发生
World J Clin Oncol. 2014 Oct 10;5(4):677-92. doi: 10.5306/wjco.v5.i4.677.
4
CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer.CD8 +肿瘤浸润淋巴细胞和COX2表达可能预测分化型甲状腺癌的复发。
Clin Endocrinol (Oxf). 2015 Aug;83(2):246-53. doi: 10.1111/cen.12586. Epub 2014 Sep 22.
5
Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids.环氧化酶-2 抑制剂是一种强有力的增强剂,可增强抗癌药物对肝癌多细胞球体的作用。
Onco Targets Ther. 2014 Feb 24;7:353-63. doi: 10.2147/OTT.S56115. eCollection 2014.
6
Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.索拉非尼与塞来昔布联合使用可在体外和体内协同抑制非小细胞肺癌细胞的肿瘤生长。
Oncol Rep. 2014 Apr;31(4):1954-60. doi: 10.3892/or.2014.3026. Epub 2014 Feb 18.
7
Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness.Cox-2 在人乳腺癌细胞中的表达作为上皮间质转化和侵袭性的关键决定因素。
Expert Opin Ther Targets. 2014 Feb;18(2):121-35. doi: 10.1517/14728222.2014.860447. Epub 2013 Dec 11.
8
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.细胞因子治疗进展后接受舒尼替尼和索拉非尼治疗的转移性肾细胞癌患者的临床和实验室预后因素
Urol Oncol. 2014 May;32(4):488-95. doi: 10.1016/j.urolonc.2013.09.011. Epub 2013 Dec 8.
9
Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice.环氧化酶-2 抑制剂抑制裸鼠前列腺癌骨转移的肿瘤进展。
BJU Int. 2014 May;113(5b):E164-77. doi: 10.1111/bju.12503. Epub 2014 Feb 14.
10
BRG1 and BRM chromatin-remodeling complexes regulate the hypoxia response by acting as coactivators for a subset of hypoxia-inducible transcription factor target genes.BRG1 和 BRM 染色质重塑复合物通过作为一部分低氧诱导转录因子靶基因的共激活因子来调节低氧反应。
Mol Cell Biol. 2013 Oct;33(19):3849-63. doi: 10.1128/MCB.00731-13. Epub 2013 Jul 29.